Skip to main content
S&P 5007,659.44-1.09%DOW52,002.41-0.34%NASDAQ26,140.03-2.14%BTC$81,442.00-0.92%ETH$2,417.14-0.81%GOLD$4,186.70+0.40%OIL$99.04+2.63%
Smart Investors Daily
SID Premium
IN

NASDAQ · INM

InMed Pharmaceuticals Inc.

Healthcare · Biotechnology

$1.32

Down-$0.01 (-0.75%)

Updated Oct 18, 2026, 1:52 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.52M
P/E ratio
-0.17
Dividend yield
0.00%
52-week range
$0.58 – $2.33
Volume
4.36K
Avg. volume
346.51K

Price performance · INM

INM price history

1M range · 0 trading sessions · Daily adjusted prices

INM does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest INM news

The latest Smart Investors Daily articles mentioning INM.

Stock researchCompany · Overview

INM research

Overview

Company profile and research snapshot.

Company profile

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
INM recent ratings
DateFirmRatingTarget
Nov 29, 2021HC Wainwright & Co.Buy—
Feb 16, 2021Roth CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 18, 2026

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' equity of $1,075,007 as reported in the...

Yahoo · Sep 9, 2026

InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026.The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com,...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By